[1] Urabe H, et al. Discovery of MGS0274, an ester prodrug of a metabotropic glutamate receptor 2/3 agonist with improved oral bioavailability [published online ahead of print, 2020 Jul 5]. Eur J Med Chem. 2020;203:112521. DOI:
10.1016/j.ejmech.2020.112521[2] Kinoshita K, et al. Preclinical disposition of MGS0274 besylate, a prodrug of a potent group II metabotropic glutamate receptor agonist MGS0008 for the treatment of schizophrenia. Pharmacol Res Perspect. 2019;7(5):e00520. Published 2019 Sep 13. DOI:
10.1002/prp2.520